In a new front in the war on illicit drugs, the U.S. Treasury has sanctioned a China-based chemical company and its executives. The action, taken in collaboration with the FBI and DEA, targets the foreign source of lethal synthetic opioids and dangerous cutting agents that are fueling America's deadly overdose epidemic.
On September 3, 2025, the U.S. Treasury Department’s Office of Foreign Assets Control (OFAC) announced sanctions against a China-based chemical company, Guangzhou Tengyue Chemical Co., Ltd., and two of its executives, Huang Xiaojun and Huang Zhanpeng. This move is a direct response to the company’s alleged role in manufacturing and distributing synthetic opioids and dangerous cutting agents to the U.S. This decisive action, carried out in conjunction with the FBI and DEA, highlights the U.S. government’s multifaceted approach to disrupting the international supply chains that are fueling the nation’s opioid crisis.
The sanctions target a company that has been actively contributing to a public health emergency. As noted by the Treasury Department, opioid overdose remains the leading cause of death for Americans aged 18 to 45. Over 70% of reported drug overdose deaths since 2021 have involved synthetic opioids, with fentanyl being a primary driver. Guangzhou Tengyue is accused of not only selling synthetic opioids but also trafficking dangerous analgesic chemicals, like xylazine (known as “tranq”) and nitazenes.
These substances are particularly lethal. Nitazenes are synthetic opioids far more potent than fentanyl, while xylazine and similar chemicals are veterinary sedatives used as cutting agents. The grave danger of these adulterants is that they do not respond to the overdose-reversing effects of Narcan, drastically increasing the likelihood of death. Despite a previous indictment in October 2024, the company allegedly continued its operations, even advertising these deadly substances on its website.
The U.S. government’s response is a powerful blend of financial and legal tools. OFAC’s sanctions block all property and interests of Guangzhou Tengyue and its sanctioned executives within the U.S., effectively cutting them off from the American financial system. This action is rooted in Executive Order 14059, which targets entities materially contributing to the international proliferation of illicit drugs.
In a parallel development, the FBI announced a federal criminal indictment against the company and its key individuals for conspiracy to commit drug trafficking. This indictment, which names approximately 22 individuals and businesses in China, is the result of a joint investigation that began in January 2024.
A key detail in this crackdown is the use of cryptocurrency by the trafficking network. OFAC’s designation included a Bitcoin address linked to Huang Xiaojun, highlighting how digital assets are used to facilitate cross-border illicit drug sales. The address, active since 2021, received over $1.2 million from various sources, including crypto ATMs and darknet marketplaces. This underscores the growing importance of on-chain analysis in law enforcement and the need for crypto compliance teams to monitor and adapt to these evolving threats.
This latest action signals a proactive and aggressive stance by the U.S. government. Under Secretary for Terrorism and Financial Intelligence John K. Hurley stated, “Illicit opioids coming from China are destroying American lives, families, and communities.” The goal is not just to punish but to dismantle the financial and operational infrastructure that enables these dangerous networks. By targeting the source of these chemicals and the individuals and financial channels that support them, U.S. authorities aim to disrupt the flow of these deadly substances before they reach American streets.